Available Until 5/30/2023

Infectious Diseases Pharmacy Specialty Review Course, Workbook Chapters and PRACTICE Exam Package (No Recert Credit ) (Cert # L229161)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 05/25/2022
Content Release Date: 06/22/2022
Expiration Date: 05/30/2023
Activity Type: Application-based
CE Credits: 25 contact hours (ACPE only)
Activity Fee: $425 (ASHP member); $625 (non-member)

Activity Overview

This online course provides a robust preparatory curriculum for the pharmacy professional preparing for the Board of Pharmacy Specialties (BPS) Infectious Diseases Specialty Certification Examination. Designed based on the domains, tasks, and knowledge statements developed by the BPS for the certification examination, this course will help you prepare for the exam by identifying areas needed for in‐depth review of infectious diseases issues by:

  • Reviewing pertinent clinical topics and practice skills
  • Providing exam practice questions
  • Listing valuable references for further study

This course is NOT intended for those obtaining recertification credit. To earn recertification credit, please see courses here: http://elearning.ashp.org/catalog/ID-recert 

These activities are part of the ASHP and ACCP professional development program. 

The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity is part of the ASHP Infectious Diseases Pharmacy Specialty Review Course, which is designed for pharmacists seeking to update their knowledge and skills in preparation for board certification.

This course consists of 15 activities (see table below) and provides up to 25 contact hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios, a practice exam along with correct answers, and links to the reference sources, and domains, tasks, and knowledge statements. To help you further prepare, this package includes a compilation of practice questions in the same format and rigor to help you prepare for the BPS Specialty Examination.       

Learning Activity

ACPE Number

Contact Hours

Expiration Date

Antimicrobial Stewardship

0204-9999-22-960-H01-P

1.50

 

 

 

 

 6/22/2025

Upper Respiratory Tract Infections

0204-9999-22-961-H01-P

2.00

Lower Respiratory Tract Infections

0204-9999-22-962-H01-P

1.50

HIV Infection and AIDS

0204-9999-22-963-H02-P

2.00

Infections of Reproductive Organs and Sexually-Transmitted Diseases

0204-9999-22-964-H01-P

1.50

Opportunistic Infections in Immunocompromised Patients

0204-9999-22-965-H01-P

1.50

Gastrointestinal and Intra-abdominal Infections

0204-9999-22-966-H01-P

1.50

Viral Hepatitis

0204-9999-22-967-H01-P

2.00

Tuberculosis and Other Mycobacterial Infections

0204-9999-22-968-H01-P

1.50

Cardiovascular Infections

0204-9999-22-969-H01-P

1.50

Urinary Tract Infections

0204-9999-22-970-H01-P

1.50

Bone and Joint Infections and Skin and Soft Tissue Infections

0204-9999-22-971-H01-P

1.50

Central Nervous System Infections

0204-9999-22-972-H01-P

1.50

Clinical Microbiology

0204-9999-22-973-H01-P

2.00

Statistics, Evidence-based Medicine, and Research Design

0204-9999-22-905-H04-P

2.00

3/4/2025

After participating in this CPE activity, learners should be able to: 

Antimicrobial Stewardship
ACPE #: 0204-9999-22-960-H01-P

  • Outline components of an effective stewardship program.
  • Select appropriate resources; relevant accreditation, legal, regulatory, and safety requirements; and quality metrics related to infectious diseases.
  • Evaluate institutional treatment policies and pathways for compliance with antimicrobial stewardship guidelines, surveillance data, and best available evidence.
  • Assess the effectiveness of infection prevention strategies.
  • Identify metrics for evaluating the value of infectious diseases pharmacy services. 

Upper Respiratory Tract Infections
ACPE #: 0204-9999-22-961-H01-P

  • Assess pharmacotherapies for upper respiratory tract infections.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
  • Recommend modifications of patient-specific treatment plans based on efficacy and adverse effects.
  • Identify recommended immunizations and potential adverse effects. 

Lower Respiratory Tract Infections
ACPE #: 0204-9999-22-962-H01-P

  • Assess pharmacotherapies for lower respiratory tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend the most appropriate modifications of patient‐specific treatment plans based on efficacy, adverse effects, and follow‐up assessment.
  • Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with lower respiratory tract infections. 

HIV Infection and AIDS
ACPE #: 0204-9999-22-963-H02-P

  • Assess pharmacotherapies for HIV‐infection and AIDS, including opportunistic infections.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • List recommended immunizations and screening guidelines for patients with HIV.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, drug interactions, immunologic or virologic response, and adverse effects.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results related to HIV infection.
  • Evaluate a plan to facilitate transitions of care. 

Infections of Reproductive Organs and Sexually Transmitted Diseases
ACPE #: 0204-9999-22-964-H01-P

  • Assess pharmacotherapies for infections of reproductive organs and sexually transmitted diseases.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Identify recommended screening guidelines for sexually‐transmitted diseases.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Summarize key considerations in effective patient and caregiver education and counseling techniques. 

Opportunistic Infections in Immunocompromised Patients
ACPE #: 0204-9999-22-965-H01-P

  • Assess the advantages and disadvantages of pharmacotherapies for opportunistic infections in immunocompromised patients, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
  • Identify preventative therapies in immunocompromised patients. 

Gastrointestinal and Intra-abdominal Infections
ACPE #: 0204-9999-22-966-H01-P

  • Assess pharmacotherapies for gastrointestinal and intra‐abdominal infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects. 

Viral Hepatitis
ACPE #: 0204-9999-22-967-H01-P

  • Assess pharmacotherapies for viral hepatitis, including relevant pharmacology and spectrum of activity.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, virus and genotype, and best available evidence.
  • Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
  • Recommend modifications of patient‐specific treatment plans based on efficacy, adverse effects, and drug interactions.
  • Summarize key considerations in effective patient and caregiver education and counseling techniques.
  • Identify screening guidelines and preventive therapies for viral hepatitis. 

Tuberculosis and Other Mycobacterial Infections
ACPE #: 0204-9999-22-968-H01-P

  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
  • Recommend modifications of patient-specific treatment plans based on efficacy, adverse effects, and drug interactions.
  • Outline key considerations in effective patient and caregiver education and counseling techniques.
  • Identify screening guidelines and preventive therapies for tuberculosis and other mycobacterial infections. 

Cardiovascular Infections
ACPE #: 0204-9999-22-969-H01-P

  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Identify drug‐related problems associated with the therapeutic plan.
  • Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
  • Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with cardiovascular infections. 

Urinary Tract Infections
ACPE #: 0204-9999-22-970-H01-P

  • Assess pharmacotherapies for urinary tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
  • Identify infectious diseases for which notification of the Centers for Disease Control and Prevention is required. 

Statistics, Evidence-based Medicine, and Research Design
ACPE #: 0204-9999-22-905-H04-P

Given an excerpt from a study:

  • Evaluate quality and appropriateness of the excerpt, with specific attention to:
    • study design
    • statistical analysis
    • internal/external validity
    • source of bias/confounders
    • quality of conclusions
    • interpretation of graphs
  • Explain why a statistical test is appropriate or not appropriate, based on the sample distribution, data type, and study design.
  • Interpret clinical and statistical significance for results from commonly used statistical tests.
  • Explain the strengths and limitations of different types of measures of central tendency (mean, median, and mode) and data spread (standard deviation, standard error of the mean, range, and interquartile range).
  • Evaluate odds ratio, risk/incidence rate, relative risk, number needed to treat, number needed to harm, and other risk estimates.
  • Assess whether the study applies to a specified patient population.

Bone and Joint Infections and Skin and Soft Tissue Infections
ACPE #: 0204-9999-22-971-H01-P

  • Assess the advantages and disadvantages of pharmacotherapies for bone and joint infections and skin and soft tissue infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Identify drug‐related problems associated with the therapeutic plan.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
  • Describe the etiology, diagnosis, and treatment of acute bacterial osteomyelitis and septic arthritis in pediatric patients. 

Central Nervous System Infections
ACPE #: 0204-9999-22-972-H01-P

  • Assess pharmacotherapies for central nervous system infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
  • Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
  • Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
  • Identify preventive therapies for central nervous system infections. 

Clinical Microbiology
ACPE #: 0204-9999-22-973-H01-P

  • Explain the mechanisms of antimicrobial resistance among various pathogens.
  • Identify basic microbiology laboratory procedures.
  • Interpret laboratory and other diagnostic test results relevant to the diagnosis, management, and monitoring of patients with infectious diseases.
  • Evaluate biomedical literature with regard to study design and methodology specific to infectious diseases.

Full faculty bios

Samuel L. Aitken, PharmD, MPH, BCIDP
Clinical Pharmacy Specialist - Infectious Diseases
University of Michigan Health
Ann Arbor, Michigan 

Eric Egelund, PharmD, PhD, AAHIVE
Clinical Assistant Professor
University of Florida
Jacksonville, Florida 

Kevin W. Garey, PharmD, MS, FASHP, FIDSA*
Professor and Chair
University of Houston College of Pharmacy
Houston, Texas 

Julie Harting, PharmD, BCIDP
Associate Professor / Clinical Pharmacist Specialist, Infectious Disease
Sullivan University College of Pharmacy / University of Louisville Health
Louisville, Kentucky 

Angela Huang, PharmD, BCIDP
Clinical Pharmacy Manager
Honor Health John C. Lincoln Medical Center
Phoenix, Arizona 

David Koren, PharmD, MPH, BCPS, AAHIVP
Clinical Pharmacist Specialist - Infectious Diseases / Adjunct Assistant Clinical Professor
Temple University Health System / Lewis Katz School of Medicine at Temple University
Philadelphia, Pennsylvania 

J. Nicholas O'Donnell, PharmD, MSc, BCPS
Associate Professor
Albany College of Pharmacy and Health Sciences
Albany, New York 

Natasha Pettit, PharmD, BCPS, BCIDP
Pharmacy Director of ASP and Pharmacy Clinical Coordinator, ASP/ID
University of Chicago Medicine
Chicago, Illinois 

Jessica Robinson, PharmD, BCPS, BCIDP
Associate Professor / Associate Director of Antimicrobial Stewardship
University of Charleston School of Pharmacy / Charleston Area Medical Center
Charleston, West Virginia 

Jason J. Schafer, PharmD, MPH, BCPS, BCIDP, AAHIVP*
Professor and Vice Chair, Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania 

Kayla R. Stover, PharmD, BCPS, BCIDP, FCCP, FIDSA*
Associate Professor of Pharmacy Practice
University of Mississippi School of Pharmacy
Jackson, Mississippi 

Bryan P. White, PharmD, BCPS
Infectious Diseases Clinical Pharmacist
University of Oklahoma Medical Center
Oklahoma City, Oklahoma 

Marylee Worley, PharmD, BCIDP
Assistant Professor
Nova Southeastern University College of Pharmacy
Fort Lauderdale, Florida 

Evan Zasowski, PharmD, MPH, BCIDP, BCPS*
Assistant Professor
Touro University California College of Pharmacy
Vallejo, California 

*Content matter experts

Kristi N. Hofer, Pharm.D.
Susan R. Dombrowski, M.S., RPh 

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

  • Kevin Garey: Research grant, Paratek Pharmaceuticals
  • David Koren: Advisor, Gilead; Independent Contractor, Abbvie
  • Jason Schafer: Advisor/research grant, Merck; Research grant, Gilead
  • Kayla Stover: Advisory Board, Cidara TherapeuticsKevin Garey: Research grant, Acurx; Research grant, Summit; Research grant, Tetraphase; Research grant, Paratek Pharmaceuticals 

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

Development

These activities were developed by ASHP and ACCP. 

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.